{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Placebo&page=2",
    "query": {
      "intervention": "Open Label Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T01:58:59.790Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01651143",
      "title": "Proof of Biological Activity of SAR100842 in Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "SAR100842",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for SAR100842)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2013-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2016-03-25",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01651143"
    },
    {
      "nct_id": "NCT05003687",
      "title": "Safety and Tolerability of Lu AG06474 in Healthy Young Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lu AG06474",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 79,
      "start_date": "2021-08-04",
      "completion_date": "2022-12-22",
      "has_results": false,
      "last_update_posted_date": "2023-01-09",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003687"
    },
    {
      "nct_id": "NCT06658093",
      "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Aging"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "65 Years to 90 Years"
      },
      "enrollment_count": 194,
      "start_date": "2026-03-04",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06658093"
    },
    {
      "nct_id": "NCT07716098",
      "title": "A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant"
      ],
      "interventions": [
        {
          "name": "Esketamine 56 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 84 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2026-07-23",
      "completion_date": "2029-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 3,
      "location_summary": "Redlands, California • Skokie, Illinois • New York, New York",
      "locations": [
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07716098"
    },
    {
      "nct_id": "NCT02277106",
      "title": "Evaluate SAGE-547 in Participants With Essential Tremor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "SAGE-547",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sage Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "2014-09-23",
      "completion_date": "2015-08-14",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 2,
      "location_summary": "Bingham Farms, Michigan • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277106"
    },
    {
      "nct_id": "NCT07139834",
      "title": "Pattern Separation in Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder (MDD)"
      ],
      "interventions": [
        {
          "name": "SSRI (escitalopram or sertraline)",
          "type": "DRUG"
        },
        {
          "name": "Extended-Release Memantine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07139834"
    },
    {
      "nct_id": "NCT02592434",
      "title": "Efficacy Study Of Tofacitinib In Pediatric JIA Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "CP-690,550 (tofacitinib)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 225,
      "start_date": "2016-06-10",
      "completion_date": "2019-05-16",
      "has_results": true,
      "last_update_posted_date": "2020-04-13",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 55,
      "location_summary": "Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02592434"
    },
    {
      "nct_id": "NCT02290873",
      "title": "A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colonoscopy"
      ],
      "interventions": [
        {
          "name": "Remimazolam",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paion UK Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 461,
      "start_date": "2015-03-30",
      "completion_date": "2016-04-19",
      "has_results": true,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 13,
      "location_summary": "Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02290873"
    },
    {
      "nct_id": "NCT01362205",
      "title": "Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcohol Withdrawal Delirium",
        "Alcohol Withdrawal Associated Autonomic Hyperactivity",
        "Alcohol Withdrawal Hallucinosis",
        "Alcohol Withdrawal-Induced Delirium Tremens"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denver Health and Hospital Authority",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 49,
      "start_date": "2012-03",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 7,
      "location_summary": "Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01362205"
    },
    {
      "nct_id": "NCT05217927",
      "title": "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant 75mg daily dosing",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant 75mg every other day dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1415,
      "start_date": "2022-03-04",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-17T01:58:59.790Z",
      "location_count": 30,
      "location_summary": "Tempe, Arizona • Colton, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217927"
    }
  ]
}